Latest news with #medicalimaging
Globe and Mail
29-05-2025
- Business
- Globe and Mail
STPCM Offers Accredited Investors Access to Pioneering Breast Imaging Innovation with FDA-Cleared Koning Vera™ Scanner
Sage Tap Poder Capital Management (STPCM) announced the official launch of a $5 million investment opportunity in Koning Health, the medical imaging company behind the groundbreaking Koning Vera™ 3D Breast CT Scanner. Sage Tap Poder Capital Management (STPCM) announced the official launch of a $5 million investment opportunity in Koning Health, the medical imaging company behind the groundbreaking Koning Vera™ 3D Breast CT Scanner. Norcross, GA - Sage Tap Poder Capital Management (STPCM) announced the official launch of a $5 million investment opportunity in Koning Health, the medical imaging company behind the groundbreaking Koning Vera™ 3D Breast CT Scanner. The raise will be facilitated through a dedicated Special Purpose Vehicle (SPV), providing accredited investors with a unique opportunity to support a category-defining technology in women's health. This SPV raise is conducted under Rule 506(c) of Regulation D and is open exclusively to verified accredited investors. Koning Health has received FDA clearance for the Koning Vera Breast CT the only imaging system of its kind that captures high-resolution, 3D images of breast tissue without the pain and distortion of compression. With this funding, Koning aims to rapidly scale its clinical footprint across the United States, expand payer reimbursement strategy, and accelerate commercial adoption among healthcare providers and radiologists. 'We are proud to be partnering with Koning Health at such a transformational moment in their growth journey. This offering gives our investor network access to a medtech company that is not only commercially active and FDA-approved for diagnostic 3D breast imaging, but also solving a decades-old pain point in women's healthcare by delivering high-resolution images without compression or discomfort,' said Kirk Honour, Managing Partner at STPCM. Koning's unique approach replaces the decades-old standard of painful breast compression with a fast, comfortable, and patient-friendly scan that captures a full 360-degree view of breast tissue in 7 seconds per breast ideal for dense tissue, calcification detection, and routine imaging. 'Koning is redefining how we approach breast imaging and STPCM is honored to play a strategic role in bringing this innovation to more clinics and patients,' added Honour. Investors interested in learning more about the opportunity can contact Kirk Honour at or call 888-558-5228 x803. About Sage Tap Poder Capital Management (STPCM) Sage Tap Poder Capital Management is a boutique investment firm dedicated to sourcing and structuring opportunities in high-growth private companies. Through its SPV model, STPCM empowers accredited investors to participate in transformational ventures typically reserved for institutional capital. Learn more at About Koning Health Koning is a global Health Technology company focused on improving the breast imaging industry with its patented Koning Vera Breast CT. Koning's vision is to create a revolution in medical imaging through advanced computed tomography technology that dramatically improves the way clinicians visualize and evaluate breast tissue. The Koning Vera is expected to optimize early disease detection, diagnosis, and intervention by the clinician. For more information, please visit Koning's website. Media Contact Company Name: Sage Tap Poder Contact Person: Kirk Honour Email: Send Email Phone: 888-558-5228 x803 Address: 300 SOUTHARD ST STE 207 City: KEY WEST State: Florida Country: United States Website:
Zawya
27-05-2025
- Health
- Zawya
World-leading cancer center, The Royal Marsden NHS Foundation Trust, using AI to push boundaries of cancer research
This partnership launches a large-scale, AI-powered service designed to accelerate cancer detection and treatment using medical imaging in the UK's National Health Service (NHS) The Royal Marsden NHS Foundation Trust is ranked among world's top cancer research centers Marks a milestone in the application of artificial intelligence for cancer research and clinical innovation Dubai, UAE/ London, UK – The Royal Marsden NHS Foundation Trust, a world-leading specialist cancer center, has today announced a pioneering partnership with NTT DATA, a global leader in digital business and technology services, and a leading enterprise imaging artificial intelligence (AI) and machine learning operations (MLOps) platform. Together, they have designed and built an advanced AI-powered radiology analysis service for the development and evaluation of AI in medical imaging, designed to transform cancer research and, ultimately, improve patient outcomes. AI's potential to enhance the speed and accuracy of identifying imaging biomarkers has long been recognized. Funded by a three-year grant from the UK's National Institute for Health and Care Research (NIHR), the service will be used for research at The Royal Marsden and the Institute of Cancer Research (ICR), including projects in collaboration with other research teams. This research initiative will focus on developing and evaluating AI algorithms to improve the accuracy of cancer evaluation, including sarcoma, lung, breast, brain and prostate cancers. This will lead to faster response times, more accurate diagnoses and better-targeted treatments. The service runs on a MLOps clinical imaging platform, built and operated by NTT DATA. To enable this, NTT DATA developed a bespoke AI computing solution leveraging high-performance Dell servers and utilizing the latest GPU processing capacity orchestrated by the platform, which helps test and manage AI algorithms and includes a large collection of radiology AI models. NTT DATA is also providing specialist imaging AI consulting services, helping researchers at The Royal Marsden test and evaluate emerging AI tools in real clinical settings, while extracting maximum insight and value from both in-house and commercial algorithms. 'AI has immense potential to support clinicians in diagnosing and treating cancer earlier and more precisely,' said Professor Dow-Mu Koh, Professor in Functional Cancer Imaging and Consultant Radiologist in Functional Imaging at The Royal Marsden. 'By working with NTT DATA and we've created a scalable research environment that allows us to explore the full potential of AI safely and in a way that could one day transform cancer diagnosis and treatment across the NHS.' Minister of State for Health, Karin Smyth, said: 'Our 10 Year Health Plan will modernize the NHS, replacing outdated systems with cutting-edge digital solutions. While this trial is in its early stages, it represents exactly the kind of collaboration between the NHS, industry and academia that will help build a health service fit for the future. Early detection saves lives, and innovations like AI will transform how cancer is diagnosed and treated – helping patients receive faster and more effective care.' Professor Mike Lewis, NIHR Scientific Director for Innovation, said: "Cancer is one of the biggest killers in the UK. That must change. This three-year grant will help researchers push the boundaries of AI-driven technology for cancer detection and diagnosis. "This AI-powered service represents the cutting edge of cancer research and it is going to transform treatment, better support NHS staff and ultimately change patients' lives. It is another great example of how NIHR-funded and supported research will ensure the best care is there when patients need it.' Tom Winstanley, Chief Technology Officer at NTT DATA UK & Ireland, commented: 'This service is a great example of responsible innovation in practice, showing the ethical, secure use of AI in healthcare. We are very proud to support The Royal Marsden in pushing the boundaries of cancer research.' Once the service is live, research teams at The Royal Marsden will be able to evaluate a range of AI models across several cancer types. These studies will generate critical insights into how AI can support clinical decision-making and shape future approaches to diagnosis and treatment. Through centralized interface and built-in monitoring tools, the research teams will also be able to track model performance over time, enabling faster feedback loops between development and deployment – a crucial step towards clinical translation. NTT DATA will continue to work closely with The Royal Marsden to support this next phase of research which will ultimately improve cancer care and patient outcomes. About NTT DATA NTT DATA is a $30+ billion trusted global innovator of business and technology services. We serve 75% of the Fortune Global 100 and are committed to helping clients innovate, optimize and transform for long-term success. As a Global Top Employer, we have experts in more than 50 countries and a robust partner ecosystem of established and start-up companies. Our services include business and technology consulting, data and artificial intelligence, and industry solutions, as well as the development, implementation and management of applications, infrastructure and connectivity. We are also one of the world's leading providers of digital and AI infrastructure. NTT DATA is part of NTT Group, which invests over $3.6 billion each year in R&D to help organizations and society move confidently and sustainably into the digital future. Visit us at About The Royal Marsden NHS Foundation Trust The Royal Marsden opened in 1851 as the world's first hospital dedicated to cancer diagnosis, treatment, research and education. Today it operates as a specialist cancer center and the Trust was delighted to welcome Her Royal Highness, The Princess of Wales, who became Joint Patron with His Royal Highness The Prince of Wales, in January this year. Together with its principal academic partner, The Institute of Cancer Research (ICR), The Royal Marsden is designated as the UK's only National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC) dedicated solely to cancer. The Royal Marsden and the ICR are recognized as one of the top four comprehensive cancer centers in the world for the impact of their research, influencing cancer treatment and care for all cancer patients. It is a center of excellence, pioneering the very latest in cancer treatments and technologies, as well as leading the way in innovative cancer diagnosis and education. The Royal Marsden operates from three centers, in Chelsea, Sutton and Cavendish Square in central London. It also has a Medical Day Unit in Kingston and is the founder and host of RM Partners West London Cancer Alliance, which includes St George's University Hospitals NHS Foundation Trust, Imperial Healthcare NHS Trust, and other healthcare partners across northwest and southwest London. Driven by the fundamental principle that patients, entrusting their lives to The Royal Marsden, deserve the very best, The Royal Marsden is committed to delivering excellent research‑led cancer care for patients, accelerating early diagnosis, and ensuring treatment and care is personalized for the needs of each individual.
National Post
27-05-2025
- Health
- National Post
World-Leading Cancer Center, The Royal Marsden NHS Foundation Trust, Using AI to Push Boundaries of Cancer Research With NTT DATA and CARPL.ai
Article content This partnership launches a large-scale, AI-powered service designed to accelerate cancer detection and treatment using medical imaging in the UK's National Health Service (NHS) The Royal Marsden NHS Foundation Trust is ranked among world's top cancer research centers Marks a milestone in the application of artificial intelligence for cancer research and clinical innovation Article content Article content LONDON — The Royal Marsden NHS Foundation Trust, a world-leading specialist cancer center, has today announced a pioneering partnership with NTT DATA, a global leader in digital business and technology services, and a leading enterprise imaging artificial intelligence (AI) and machine learning operations (MLOps) platform. Together, they have designed and built an advanced AI-powered radiology analysis service for the development and evaluation of AI in medical imaging, designed to transform cancer research and, ultimately, improve patient outcomes. Article content AI's potential to enhance the speed and accuracy of identifying imaging biomarkers has long been recognized. Funded by a three-year grant from the UK's National Institute for Health and Care Research (NIHR), the service will be used for research at The Royal Marsden and the Institute of Cancer Research (ICR), including projects in collaboration with other research teams. This research initiative will focus on developing and evaluating AI algorithms to improve the accuracy of cancer evaluation, including sarcoma, lung, breast, brain and prostate cancers. This will lead to faster response times, more accurate diagnoses and better-targeted treatments. Article content The service runs on a MLOps clinical imaging platform, built and operated by NTT DATA. To enable this, NTT DATA developed a bespoke AI computing solution leveraging high-performance Dell servers and utilizing the latest GPU processing capacity orchestrated by the platform, which helps test and manage AI algorithms and includes a large collection of radiology AI models. Article content NTT DATA is also providing specialist imaging AI consulting services, helping researchers at The Royal Marsden test and evaluate emerging AI tools in real clinical settings, while extracting maximum insight and value from both in-house and commercial algorithms. Article content 'AI has immense potential to support clinicians in diagnosing and treating cancer earlier and more precisely,' said Professor Dow-Mu Koh, Professor in Functional Cancer Imaging and Consultant Radiologist in Functional Imaging at The Royal Marsden. 'By working with NTT DATA and we've created a scalable research environment that allows us to explore the full potential of AI safely and in a way that could one day transform cancer diagnosis and treatment across the NHS.' Article content Minister of State for Health, Karin Smyth, said: 'Our 10 Year Health Plan will modernize the NHS, replacing outdated systems with cutting-edge digital solutions. While this trial is in its early stages, it represents exactly the kind of collaboration between the NHS, industry and academia that will help build a health service fit for the future. Early detection saves lives, and innovations like AI will transform how cancer is diagnosed and treated – helping patients receive faster and more effective care.' Article content Professor Mike Lewis, NIHR Scientific Director for Innovation, said: 'Cancer is one of the biggest killers in the UK. That must change. This three-year grant will help researchers push the boundaries of AI-driven technology for cancer detection and diagnosis. Article content 'This AI-powered service represents the cutting edge of cancer research and it is going to transform treatment, better support NHS staff and ultimately change patients' lives. It is another great example of how NIHR-funded and supported research will ensure the best care is there when patients need it.' Article content Tom Winstanley, Chief Technology Officer at NTT DATA UK & Ireland, commented: 'This service is a great example of responsible innovation in practice, showing the ethical, secure use of AI in healthcare. We are very proud to support The Royal Marsden in pushing the boundaries of cancer research.' Article content Once the service is live, research teams at The Royal Marsden will be able to evaluate a range of AI models across several cancer types. These studies will generate critical insights into how AI can support clinical decision-making and shape future approaches to diagnosis and treatment. Through centralized interface and built-in monitoring tools, the research teams will also be able to track model performance over time, enabling faster feedback loops between development and deployment – a crucial step towards clinical translation. NTT DATA will continue to work closely with The Royal Marsden to support this next phase of research which will ultimately improve cancer care and patient outcomes. Article content About NTT DATA Article content NTT DATA is a $30+ billion trusted global innovator of business and technology services. We serve 75% of the Fortune Global 100 and are committed to helping clients innovate, optimize and transform for long-term success. As a Global Top Employer, we have experts in more than 50 countries and a robust partner ecosystem of established and start-up companies. Our services include business and technology consulting, data and artificial intelligence, and industry solutions, as well as the development, implementation and management of applications, infrastructure and connectivity. We are also one of the world's leading providers of digital and AI infrastructure. NTT DATA is part of NTT Group, which invests over $3.6 billion each year in R&D to help organizations and society move confidently and sustainably into the digital future. Article content The Royal Marsden opened in 1851 as the world's first hospital dedicated to cancer diagnosis, treatment, research and education. Today it operates as a specialist cancer center and the Trust was delighted to welcome Her Royal Highness The Princess of Wales, who became Joint Patron with His Royal Highness The Prince of Wales, in January this year. Article content Together with its principal academic partner, The Institute of Cancer Research (ICR), The Royal Marsden is designated as the UK's only National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC) dedicated solely to cancer. Article content The Royal Marsden and the ICR are recognized as one of the top four comprehensive cancer centers in the world for the impact of their research, influencing cancer treatment and care for all cancer patients. It is a center of excellence, pioneering the very latest in cancer treatments and technologies, as well as leading the way in innovative cancer diagnosis and education. Article content The Royal Marsden operates from three centers, in Chelsea, Sutton and Cavendish Square in central London. It also has a Medical Day Unit in Kingston, and is the founder and host of RM Partners West London Cancer Alliance, which includes St George's University Hospitals NHS Foundation Trust, Imperial Healthcare NHS Trust, and other healthcare partners across north west and south west London. Article content Article content Article content Article content Article content Article content
Yahoo
27-05-2025
- Business
- Yahoo
World-Leading Cancer Center, The Royal Marsden NHS Foundation Trust, Using AI to Push Boundaries of Cancer Research With NTT DATA and CARPL.ai
This partnership launches a large-scale, AI-powered service designed to accelerate cancer detection and treatment using medical imaging in the UK's National Health Service (NHS) The Royal Marsden NHS Foundation Trust is ranked among world's top cancer research centers Marks a milestone in the application of artificial intelligence for cancer research and clinical innovation LONDON, May 27, 2025--(BUSINESS WIRE)--The Royal Marsden NHS Foundation Trust, a world-leading specialist cancer center, has today announced a pioneering partnership with NTT DATA, a global leader in digital business and technology services, and a leading enterprise imaging artificial intelligence (AI) and machine learning operations (MLOps) platform. Together, they have designed and built an advanced AI-powered radiology analysis service for the development and evaluation of AI in medical imaging, designed to transform cancer research and, ultimately, improve patient outcomes. AI's potential to enhance the speed and accuracy of identifying imaging biomarkers has long been recognized. Funded by a three-year grant from the UK's National Institute for Health and Care Research (NIHR), the service will be used for research at The Royal Marsden and the Institute of Cancer Research (ICR), including projects in collaboration with other research teams. This research initiative will focus on developing and evaluating AI algorithms to improve the accuracy of cancer evaluation, including sarcoma, lung, breast, brain and prostate cancers. This will lead to faster response times, more accurate diagnoses and better-targeted treatments. The service runs on a MLOps clinical imaging platform, built and operated by NTT DATA. To enable this, NTT DATA developed a bespoke AI computing solution leveraging high-performance Dell servers and utilizing the latest GPU processing capacity orchestrated by the platform, which helps test and manage AI algorithms and includes a large collection of radiology AI models. NTT DATA is also providing specialist imaging AI consulting services, helping researchers at The Royal Marsden test and evaluate emerging AI tools in real clinical settings, while extracting maximum insight and value from both in-house and commercial algorithms. "AI has immense potential to support clinicians in diagnosing and treating cancer earlier and more precisely," said Professor Dow-Mu Koh, Professor in Functional Cancer Imaging and Consultant Radiologist in Functional Imaging at The Royal Marsden. "By working with NTT DATA and we've created a scalable research environment that allows us to explore the full potential of AI safely and in a way that could one day transform cancer diagnosis and treatment across the NHS." Minister of State for Health, Karin Smyth, said: "Our 10 Year Health Plan will modernize the NHS, replacing outdated systems with cutting-edge digital solutions. While this trial is in its early stages, it represents exactly the kind of collaboration between the NHS, industry and academia that will help build a health service fit for the future. Early detection saves lives, and innovations like AI will transform how cancer is diagnosed and treated – helping patients receive faster and more effective care." Professor Mike Lewis, NIHR Scientific Director for Innovation, said: "Cancer is one of the biggest killers in the UK. That must change. This three-year grant will help researchers push the boundaries of AI-driven technology for cancer detection and diagnosis. "This AI-powered service represents the cutting edge of cancer research and it is going to transform treatment, better support NHS staff and ultimately change patients' lives. It is another great example of how NIHR-funded and supported research will ensure the best care is there when patients need it." Tom Winstanley, Chief Technology Officer at NTT DATA UK & Ireland, commented: "This service is a great example of responsible innovation in practice, showing the ethical, secure use of AI in healthcare. We are very proud to support The Royal Marsden in pushing the boundaries of cancer research." Once the service is live, research teams at The Royal Marsden will be able to evaluate a range of AI models across several cancer types. These studies will generate critical insights into how AI can support clinical decision-making and shape future approaches to diagnosis and treatment. Through centralized interface and built-in monitoring tools, the research teams will also be able to track model performance over time, enabling faster feedback loops between development and deployment – a crucial step towards clinical translation. NTT DATA will continue to work closely with The Royal Marsden to support this next phase of research which will ultimately improve cancer care and patient outcomes. About NTT DATA NTT DATA is a $30+ billion trusted global innovator of business and technology services. We serve 75% of the Fortune Global 100 and are committed to helping clients innovate, optimize and transform for long-term success. As a Global Top Employer, we have experts in more than 50 countries and a robust partner ecosystem of established and start-up companies. Our services include business and technology consulting, data and artificial intelligence, and industry solutions, as well as the development, implementation and management of applications, infrastructure and connectivity. We are also one of the world's leading providers of digital and AI infrastructure. NTT DATA is part of NTT Group, which invests over $3.6 billion each year in R&D to help organizations and society move confidently and sustainably into the digital future. Visit us at About The Royal Marsden NHS Foundation Trust The Royal Marsden opened in 1851 as the world's first hospital dedicated to cancer diagnosis, treatment, research and education. Today it operates as a specialist cancer center and the Trust was delighted to welcome Her Royal Highness The Princess of Wales, who became Joint Patron with His Royal Highness The Prince of Wales, in January this year. Together with its principal academic partner, The Institute of Cancer Research (ICR), The Royal Marsden is designated as the UK's only National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC) dedicated solely to cancer. The Royal Marsden and the ICR are recognized as one of the top four comprehensive cancer centers in the world for the impact of their research, influencing cancer treatment and care for all cancer patients. It is a center of excellence, pioneering the very latest in cancer treatments and technologies, as well as leading the way in innovative cancer diagnosis and education. The Royal Marsden operates from three centers, in Chelsea, Sutton and Cavendish Square in central London. It also has a Medical Day Unit in Kingston, and is the founder and host of RM Partners West London Cancer Alliance, which includes St George's University Hospitals NHS Foundation Trust, Imperial Healthcare NHS Trust, and other healthcare partners across north west and south west London. Driven by the fundamental principle that patients, entrusting their lives to The Royal Marsden, deserve the very best, The Royal Marsden is committed to delivering excellent research‑led cancer care for patients, accelerating early diagnosis, and ensuring treatment and care is personalized for the needs of each individual. View source version on Contacts Hotwire Globalnttdata@ Sign in to access your portfolio
Associated Press
21-05-2025
- Business
- Associated Press
AI in Ultrasound Imaging Market Research 2025-2035 Featuring GE, Siemens Healthineers, Fujifilm, Canon Medical, EchoNous, Samsung, Butterfly Network, NovaSignal, Esaote, Exo AI, and Clarius
DUBLIN--(BUSINESS WIRE)--May 21, 2025-- The 'Global AI in Ultrasound Imaging Market: Analysis and Forecast, 2025-2035" report has been added to offering. Ultrasound imaging is a medical diagnostic technique that uses high-frequency sound waves to produce real-time images of the inside of the body. It is widely used in medical fields to visualize tissues, organs, and developing foetuses, among others. AI in ultrasound imaging is transforming the medical imaging landscape by significantly enhancing diagnostic accuracy, minimizing human error, and optimizing workflow efficiency. The market is experiencing accelerated adoption fueled by rising demand for automation in healthcare, broader ultrasound utilization across various medical fields, and continuous advancements in AI-driven imaging solutions. With deep learning algorithms becoming integral to ultrasound systems, the global market is poised for substantial growth. By 2035, the AI in ultrasound imaging market is expected to expand robustly, with key applications spanning cardiology, obstetrics, orthopedics, and gastroenterology. These AI-powered solutions will be pivotal in early disease detection, workflow optimization, and reducing reliance on highly specialized radiologists. Market growth will be further propelled by supportive regulatory frameworks, increased investments in AI healthcare, and the growing demand for cost-efficient diagnostic tools. Artificial intelligence (AI) is transforming ultrasound imaging by improving diagnostic accuracy, especially in identifying fetal abnormalities, heart conditions, and tumors. Moreover, the increasing emphasis on early diagnosis to improve patient outcomes and reduce healthcare costs is accelerating the adoption of AI-powered imaging solutions. Also, governments and healthcare organizations are actively promoting AI-based technologies to enhance efficiency in medical diagnostics. In the U.S., the National Artificial Intelligence Initiative Act of 2020 established a coordinated program to advance AI research and applications, aiming to maintain the nation's leadership in AI and ensure its use in the public and private sectors. These initiatives underscore the commitment to integrating AI into healthcare practices, facilitating more accurate and timely disease detection, and ultimately improving patient care. In addition, the growing development of portable, AI-powered ultrasound devices is expected to drive the market over a forecast period. These handheld solutions offer real-time, AI-driven diagnostics, making them essential for point-of-care applications, particularly in remote or emergency settings. Companies such as Butterfly Network and Clarius are at the forefront of these innovations, with their AI-integrated, portable systems revolutionizing healthcare delivery. The integration of cloud-based AI for remote diagnostics is enhancing the capabilities of these devices, expanding their use in underserved and rural areas. Moreover, emerging markets in the Asia-Pacific, Latin America, and Middle East regions represent substantial growth opportunities for AI-powered ultrasound imaging. Increased healthcare investments, government-driven digital healthcare transformation initiatives, and the demand for cost-efficient diagnostic solutions are driving the adoption of AI in these areas. For instance, India's National Health Mission is investing in AI technologies to enhance healthcare delivery in rural areas. Additionally, AI-powered tele-ultrasound solutions are expanding access to diagnostic services in remote and underserved regions, allowing for remote consultations and diagnoses. However, the implementation of AI in ultrasound imaging comes with significant costs related to software development, hardware integration, and regulatory approvals. Many hospitals and diagnostic centers, especially in developing regions, face budget constraints that limit their ability to invest in AI-based imaging solutions. Additionally, integrating AI with existing ultrasound systems and ensuring regulatory compliance remain challenges for market growth. Leading players in the AI-driven ultrasound imaging market are employing various strategies to strengthen their competitive position. For instance, GE Healthcare focuses on AI-enabled imaging solutions that streamline clinical workflows and assist in early disease detection, while also collaborating through the National Consortium of Intelligent Medical Imaging (NCIMI) to advance AI in medical imaging. Key players in the market are General Electric (GE) Company, Siemens Healthineers, Fujifilm Holdings Corporation, Canon Medical, EchoNous, Inc., Samsung, Butterfly Network, Inc., NovaSignal Corporation, Esaote S.p.A., Exo AI, and Clarius, among others. Software to Lead the Global AI in Ultrasound Imaging Market (by Product Type) AI-powered software solutions are at the forefront of transforming ultrasound imaging by offering advanced image analysis, automated anomaly detection, and decision support for radiologists. These software applications enhance diagnostic accuracy and streamline workflows. For instance, Koios Medical has developed AI-based clinical decision support software that aids in the analysis of ultrasound images, particularly for breast and thyroid cancer diagnosis. Their Smart Ultrasound software utilizes machine learning algorithms to provide real-time assessments, improving diagnostic confidence and efficiency. Cardiology to Lead the Global AI in Ultrasound Imaging Market (by Application) In cardiology, AI is significantly enhancing the capabilities of echocardiography by improving the accuracy of heart disease detection and assessment. The increasing prevalence of cardiovascular diseases globally underscores the importance of this advancement. Such innovations enable clinicians to diagnose cardiac conditions more efficiently and accurately. Additionally, AI-powered tools are enhancing handheld ultrasound devices for cardiac imaging. Researchers have developed AI applications that guide medical personnel in positioning devices correctly, ensuring optimal image acquisition for accurate heart assessments. This advancement is particularly beneficial in point-of-care settings, facilitating timely and precise cardiac evaluations. Hospitals to Lead the Global AI in Ultrasound Imaging Market (by End User) Hospitals are the primary adopters of AI-powered ultrasound imaging due to the high patient volume and the necessity for precise diagnostics. The integration of AI-driven imaging solutions in hospital radiology and cardiology departments enhances diagnostic capabilities and operational Healthcare has developed AI-guided ultrasound systems that provide real-time feedback during scans, enabling clinicians of varying experience levels to capture high-quality images. This technology reduces the skill barrier in ultrasound imaging, allowing for broader utilization in hospital settings and improving patient care. Moreover, AI-powered ultrasound devices are being utilized to address critical healthcare needs in hospitals. For example, during the COVID-19 pandemic, AI-enhanced lung ultrasound models were developed to diagnose respiratory diseases rapidly and accurately. These models analyze ultrasound videos to detect lung abnormalities, aiding in the swift diagnosis and management of conditions like pneumonia and COVID-19. North America to Lead the Global AI in Ultrasound Imaging Market (by Region) North America leads the AI ultrasound imaging market due to its strong healthcare infrastructure, fast adoption of AI in diagnostics, and significant investments in AI technologies. The region's leadership is further supported by major players like GE Healthcare, and Siemens Healthineers, who are leading the integration of AI into medical imaging. Key Topics Covered: 1. Market 1.1 Global Market Outlook 1.1.1 Product Definition 1.1.2 Inclusion and Exclusion Criteria 1.2 Industry Outlook 1.2.1 Key Trends 1.2.2 Patent Analysis 1.2.3 Regulatory Scenario 1.2.4 Funding Scenario 1.2.5 Ongoing Clinical Trials 1.3 Business Dynamics 1.3.1 Impact Analysis 1.3.2 Business Drivers 1.3.3 Business Restraints 1.3.4 Business Opportunities 2. Global AI in Ultrasound Market (by Product Type) 2.1 Hardware 2.2 Software 3. Global AI in Ultrasound Market (by Application) 3.1 Obstetrics and Gynecology 3.2 Cardiology 3.3 Orthopedics 3.4 Gastroenterology 3.5 Others 4. Global AI in Ultrasound Imaging Market (by End User) 4.1 Hospital 4.2 Diagnostic Centers 4.3 Ambulatory Surgical Centers 4.4 Others 5. Global AI in Ultrasound Imaging Market (by Region), $Million 5.1 North America AI in Ultrasound Imaging Market 5.1.1 Market Dynamics 5.1.2 Sizing and Forecast Analysis 5.1.2.1 North America AI in Ultrasound Imaging Market (by End User) 5.1.2.2 North America AI in Ultrasound Imaging Market (by Country) 5.1.2.2.1 U.S. 5.1.2.2.1.1 Market Dynamics 5.1.2.2.1.2 Market Size and Forecast 5.1.2.2.2 Canada 5.1.2.2.2.1 Market Dynamics 5.1.2.2.2.2 Market Size and Forecast 5.2 Europe AI in Ultrasound Imaging Market 5.3 Asia-Pacific AI in Ultrasound Imaging Market 5.4 Rest-of-the-World AI in Ultrasound Imaging Market 6. Markets 6.1 Competitive Benchmarking and Company Profiles 6.1.1 Competitive Landscape 6.1.2 Key Strategies and Developments 6.1.2.1 Partnerships, Alliances, and Business Expansion 6.1.2.2 Funding Activities 6.1.2.3 New Offerings 6.1.2.4 Mergers and Acquisitions 6.1.2.5 Regulatory and Legal Activities 6.2 Company Profiles 6.2.1 Company Overview 6.2.2 Product Offerings 6.2.3 Recent Developments 6.2.4 Analyst Perspectives For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: MEDICAL DEVICES HEALTH TECHNOLOGY PHOTOGRAPHY SOFTWARE ARTIFICIAL INTELLIGENCE SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 05/21/2025 09:56 AM/DISC: 05/21/2025 09:55 AM
